Prospective multicentre clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients (NB2015-LR)

Written By 3B Digital

Chief Investigator: Thorsten Simon

Sponsor: University of Cologne

This study aims to improve the outcome of patients with low and intermediate risk neuroblastoma. The study is evaluating the use RNA expression array based treatment stratification algorithm. The primary objectives of the trial are:

  • the improvement of event free survival for Group B patients with intensified treatment

  • maintainance of event free survival of group C patients with reduced treatment after treatment allocation by gene expression-based risk stratification compared to patients of group A.

The study is open at sites across Germany.

For more details about the trials, please see: https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004883-37/DE

3B Digital https://www.3bweb.com
Previous

Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma (RIST-rNB-2011)
Next

A phase II trial of 177Lutetium-DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma (LuDO-N Trial)